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I. Introduction
Since colonial times, sexually transmitted diseases (STDs) have plagued
American society. STDs like syphilis, and more recently HIV/AIDS, have contributed
to significant morbidity and mortality in the United States. 6 Even though major
1 This article is based in part on the publication, James G. Hodge, Jr., Amy Pulver, Matthew
Hogben, Dhrubajyoti Bhattacharya, and Erin Fuse Brown, Expedited Partner Therapy: Assessing the
Legal Environment, 98 AM. J. OF PUB. HEALTH 23 (2008), and on the existing research in Centers
for Disease Control and Prevention (CDC) and Centers for Law and the Public's Health at Johns
Hopkins and Georgetown Universities, Legal Status of Expedited Partner Therapj, available at
http://www.cdc.gov/std/ept/legal/default.htm (last visited Apr. 1, 2008). Research conducted
by the Centers for Law and the Public's Health: A Collaborative at Johns Hopkins and Georgetown
Universities [hereinafter Center] is supported at the Johns Hopkins Bloomberg School of Public
Health through CDC Cooperative Agreement No. U50/CCU323385-02. The contents of this
article are solely the responsibility of the authors and do not represent the official views of CDC.
The authors acknowledge the editing and research assistance of Meredith Larson, J.D., M.P.H.
Candidate, Georgetown and Johns Hopkins Universities, and Center Researcher.
2 Associate Professor, Johns Hopkins Bloomberg School of Public Health; Executive Director,
Centers for Law and the Publics Health: A Collaborative.
3 Attorney, private practice; Senior Researcher (former), Centers for Law and the Public's Health: A
Collaborative, Johns Hopkins Bloomberg School of Public Health.
4 Global Health Law Scholar and L.L.M. Candidate, Georgetown University Law Center.
5 M.P.H. Candidate, Johns Hopkins Bloomberg School of Public Health; Senior Researcher
(former), Centers for Law and the Public's Health: A Collaborative, Johns Hopkins Bloomberg School
of Public Health.
6 Lawrence 0. Gostin & James G. Hodge, Jr., Piering the Veil of Secre in HIV/AIDS and Other
Sexual# Transmitted Diseases: Theories of Privag and Disclosure in Partner Notification, 5 DUKE J. OF
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advances have been made in detecting, treating, and preventing STDs, even common
infections such as chlamydia and gonorrhea remain significant threats to the public's
health.7 The U.S. Centers for Disease Control and Prevention (CDC) estimates that
over 700,000 new cases of gonorrhea8 and 2.8 million new cases of chlamydia 9 occur
each year in the United States. Each case affects not only the health of the person who
has contracted one or more STDs, but also threatens the health of partners with whom
infected persons engage in unprotected sexual behaviors. 10
Not surprisingly, evaluating and treating the sexual partners of infected persons
are critical components of prevention efforts" and essential to limiting the spread of
STDs.12 Traditional practices to inform, evaluate, and treat sexual partners have relied
on patients or health care providers to notify partners of their potential exposure to
STDs. 13  Partner management strategies became widely recommended for many
STDs. 14 However, these strategies, particularly concerning gonorrhea and chlamydia,
have only been marginally successful in assuring partner treatment. While assisting in
identifying and locating at-risk sexual partners, these strategies frequently do not result
in actual treatment of partners. Accordingly, untreated partners may continue to spread
STDs, including reinfecting the existing patient. Without partner treatment, the cycle of
STD transmission may continue unabated.
Public health officials recognize this limitation of existing partner management
approaches and have devised a clever solution. Expedited partner therapy, or EPT,
refers to the direct delivery of medications or prescriptions by a person infected with an
STD to his or her sex partners. No clinical assessment of the patient's sex partners is
GENDER L. & POL'Y 9 (1998).
7 Lawrence K. Altman, Sex Diseases Still Rsing" Chlatydia Is Leader, N.Y. TIMES, Nov. 14, 2007, at
A17.
8 CDC, Gonorrhea - CDC Fact Sheet, available at http://www.cdc.gov/std/Gonorrhea/STDFact-
gonorrhea.htm (last visited Apr. 1, 2008).
9 CDC, Chlanydia - CDC Fact Sheet, available at http://www.cdc.gov/std/Chlamydia/STDFact-
Chlamydia.htm (last visited Apr. 1, 2008).
lo Id.
H TH IMAS PARRAN, M.D., SHADOW ON THE LAND: SYPHILIS (Reynal & Hitchcock 1937).
12 CDC, Sexualb, Transmitted Diseases Treatment Guideines, 2006, 55 MORBIDITY AND MORTALITY
WEEKLY REP., No. RR-1 1, 5-6 (2006) (hereinafter CDC STD Disease Treatment Guideines).
13 James G. Hodge, Jr. & Lawrence 0. Gostin, Handling Cases of Wilful Exposure Through HIV
Partner Counseling and Referral Services, 23 RUTGERS WOMEN'S RTS. L. REP. 45,46 (2001).
14 CDC, Program Operations Guidelines for STD Prevention." Partner Services, PS-1, available at
http://wwwv.cdc.gov/std/program/partners.pdf (last visited Apr. 1, 2008); CDC, HIV Partner
Services and Referral Services Guidance (Dec. 30, 1998), available at http://www.cdc.gov/
hiv/resources/guidelines/pcrs/pdf/pcrs.pdf (last visited Apr. 1, 2008).
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required. Rather, health care practitioners (e.g., physicians, nurse practitioners, physician
assistants, pharmacists, and public health workers) provide patients with sufficient
medications either directly or via prescription for the patients and their partners. After
evaluating multiple studies demonstrating the efficacy of EPT as a public health measure
in specific settings, CDC recommended national use of EPT in 2006 for certain
populations with chlamydia and gonorrhea.Is
EPT can effectively reduce the prevalence and incidence of disease. By offering
safe and effective medications directly to at-risk partners without clinical evaluation,
EPT frequently increases patient-based partner notification and treatment rates,
effectively closes an existing loop of transmission, and derails the future spread of STDs
to the patient, partner, or others at risk of exposure. Yet implementation of EPT raises
significant legal and policy questions. Is it legally permissible to provide prescription
medications to the patient's partners when those partners have not undergone clinical
evaluation? Are clinicians liable or subject to licensing sanctions for "third-party
prescribing?" May patients be criminally sanctioned for providing treatment for STDs to
their partners without a valid prescription from a licensed practitioner? Can pharmacists
lawfully distribute prescription medications to patients if they know the drugs are to be
used by the patients' partners? Who should pay for the partner's medications - the
patient, the patient's health insurer, the partner, or public health authorities?
These and other concerns have the potential to stymie the practice of EPT. In
2005, Matthew Golden and colleagues surveyed state boards of medicine and pharmacy,
finding that nearly 90% of boards perceived EPT as illegal or of "uncertain" legality,
due in part to the fact that the legal issues have "simply never been addressed."' 6 To
address this gap, the Centers for Law and the Public's Health: A Collaborative at Johns Hopkins
and Georgetown Universities (Center) collaborated with CDC beginning in September 2005 to
assess the legal framework concerning EPT.'7 After conducting extensive legal reviews
across all states and other jurisdictions, we concluded that despite potential legal
impediments, the use of EPT to provide treatment and diminish the spread of STDs is
legally defensible in many states and should be promoted through laws and policies that
seek to protect the public's health.' 8
Is CDC STD Disease Treatment Guidelines, supra note 12, at 68.
16 Matthew R. Golden et al., The Legal Status of Patient-Defivered Partner Therapy for Sexual4
Transmitted Infeetions in the United States, 32 SEXUALLY TRANSMITTED DISEASES 112, 112-114
(2005).
17 Hodge et al., spra note 1, at 238-43.
18Id.
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In this article, we explain these findings and suggest a series of options to
facilitate the practice of EPT. We begin in Part II by addressing the public health
burdens of gonorrhea and chlamydia (the specific STDs for which EPT is
recommended), traditional public health approaches to partner notification, and the
efficacy (and limits) of EPT as a tool for STD prevention. 19 Part III explores key legal
issues surrounding licensing sanctions, public health requirements, liability, prescription
drug laws, and reimbursement. 20 We frame and respond to the central legal issue
underlying EPT - whether a health care practitioner ma provide a prescription for a non-controlkd
substance to a patient's sexual partner, absent prior evaluation of the partner, for the purposes of
treating the partnerfor pedfic STDs. 21 Part IV examines the legality of EPT across all states,
D.C., and Puerto Rico by presenting the methodology and results of the legal assessment
by the Center and CDC.z2 Through this analysis, we find that EPT is legally (1) permissibk
in 12 (23%) jurisdictions, (2) potentialy allowable in 27 (52%) jurisdictions, and (3)
prohibited in only 13 (25%) jurisdictions. 23 These findings suggest that the legal landscape
in many jurisdictions supports, rather than rejects, the practice of EPT.
Still, significant legal and policy challenges confront practitioners trying to
implement EPT in many states. In Part V, we proffer several law and policy options
designed to facilitate the implementation of EPT to improve the public's health.24
These include select reforms to: (1) expressly endorse EPT through statutory or
regulatory enactments, facilitated by the creation of model statutory language; (2) adopt
modem, updated national treatment guidelines; (3) create exceptions to constrictive
prescription drug requirements; (4) seek increased medical or pharmaceutical board
support for EPT; and (5) support insurance payments for partners' medications
provided through patients.25
II. EPT as a Tool for Public Health Prevention of Specific STDs
The emerging use of EPT as a tool for public health prevention is focused on
STDs like chlamydia and gonorrhea that are proliferate across the United States,
relatively easy to treat, and susceptible to reinfection.26 STDs such as HIV/AIDS or
19 See discussion infra Part II.
20 See discussion infra Part III.
21 See discussion infra Part III.
22 See discussion infra Part IV.
23 See discussion infra Part IV(B).
24 See discussion infra Part V.
25 Id.
26 See Hodge, et al., supra note 1.
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syphilis that involve complex treatment regimens are not suitable conditions for the use
of EPT because ongoing clinical care is essential to successful treatment.27 Chlamydia
trachomatis infection is the most commonly reported notifiable condition 28 in the United
States with more than 1.031 million actual cases reported to state and local health
departments in 2006, the most recent year for which surveillance data are available.2 9 N.
gonorrhoeae is the second most reported condition nationally with more than 358,000
cases reported in 2006.30 Reported cases represent only a fraction of the true incidence
of these infections because many cases are asymptomatic and not detected, or are simply
not reported. 31 CDC estimates that 2.8 million Americans are infected with chlamydia
32
and about 700,000 are infected with gonorrhea33 each year. African Americans are
disproportionately affected: according to CDC, the ratio of infections between African
Americans and Caucasians is 18:1 for gonorrhea, and 8:1 for chlamydia. 34
Morbidity of these infections is significant because they are so common and can
lead to long-term disabilities when untreated. 35 Both chlamydia and gonorrhea can
result in serious complications, leading to high health care costs, especially among
African-American women. 36 In men, gonorrhea can cause epididymitis, an infection in
27 Id
28 See Altman, supra note 7. For background on the CDC's collection and publication of data on
nationally notifiable diseases and the most recent listing of them, see CDC, National4 Nodtfiable
Diseases Suvillance System, at http://www.cdc.gov/epo/ dphsi/nndsshis.htm (last visited Apr. 1,
2008).
29 See Altman, supra note 7.
30 Id.
31 S. Deblina Datta, et al., Gonorrhea and Chlamydia in the United States Among Persons 14 to 39 Years of
Age, 1999 to 2002, 147 ANNALS INTERNAL MED. 89, 89.
32 See Chlamydia - CDC Fact Sheet, supra note 9.
33 See Gonorrhea - CDC Fact Sheet, supra note 8.
34 See Altman, supra note 7. Interestingly, these racial disparities are not explained by differences
in socioeconomic status or health behaviors such as illicit drug use, condom use or concurrence
of sex partners, suggesting that population-level interventions such as the practice of EPT might
be the most effective means for addressing racial disparities. See Denise Dion Hallfors, et al.,
Sexual and Drug Behavior Patterns and HIV and STD Racial Diparities: The Need for New Directions, 97
AM. J PUB. HEALTH 126-32 (2007) ("factors other than individual risk behaviors and covariates
appear to account for racial disparities, indicating the need for population level interventions.');
Thomas A. Farley, Sexual# Transmitted Diseases in the Southeastern United States: Location, Race, and
Social Context, 33 SEXUALLY TRANSMITTED DISEASES S58-S64 (2006) ("the racial disparity cannot
be explained by traditional measures of socioeconomic differences, and it cannot be explained by
individual-level determinants of sexual behavior, but rather reflects deeper group-level social and
environmental factors for which race is a marker.").
35 See Chlamydia - CDC Fact Sheet, supra note 9.
36 See Joanna E. Siegel, The Economic Burden of Sexual# Transmitted Disease in the United States, in
2008
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the reproductive organ that is usually not serious but can lead to abscess or infertility if
untreated. For women, chlamydia and gonorrhea are major causes of pelvic
inflammatory disease, an infection of the reproductive organs that can lead to infertility,
ectopic pregnancy, abscess formation, and chronic pelvic pain.37 Pregnant women can
pass the infection to their infants during delivery, which can lead to neonatal ophthalmia
(an eye infection that can lead to blindness if untreated) and pneumonia. Recurrent
infections with chlamydia and gonorrhea persists, particularly among sexually active
young women, 38 and increase the risk of short- and long-term complications, 39 including
the transmission of HIV infection. 4°
A. Traditional Treatment Approaches
One of the most significant impediments to controlling the spread of STDs like
chlamydia and gonorrhea is that "the sexual partners of people with sexually transmitted
infections are likely to be infected but may be asymptomatic and may not otherwise seek
care." 41 For this reason, once a person is known to be infected with an STD, identifying
and treating others who may be at risk of infection is a long-standing public health goal.
Traditional strategies to identify, inform, evaluate, and treat infected patients' sex
partners have relied upon index patients and/or their health care providers to notif
"
sexual partners that they should seek testing and appropriate medical care.42 Partner
management practices (including contact tracing 43 and partner notification, 44 or, as more
SEXUALLY TRANSMITTED DISEASES 1367 (King K Holmes, et al., eds., 3d ed. 1999).
37 CDC, Pelvic Inflammatoy Disease - CDC Fact Sheet, available at http://www.cdc.gov/std/PID/
STDFact-PID.htm (last visited Apr. 1, 2008).
38 See Linda M. Niccolai, et al., Burden of Recurrent Chlatrydia Trachomatis Infections in Young Women:
Further Uncovering the '1Hidden Epidemic," 161 ARCHIVES OF PEDIATRICS AND ADOLESCENT IED.
246 (2007).
39 Researchers have estimated that as much as 48% of the morbidity of gonorrhea is attributable
to reinfection. See Kyle T. Bernstein, et al., Defining Core Gonorrhea Transmission Utiling Spatial
Data, 160 AM. J. EPIDEMIOLOGY 51 (2004). See also Susan D. Hillis, et al., Recurrent Chlaodial
Infections Increase the Risks of Hospitalzation for Ectopic Pregnany and Pelvic Inflammatory Disease, 176
AM. J. OBSTETRICS & GYNECOLOGY 103 (1997); Jami S. Leichliter, et al., STD REPEATERS:
IMPLICATIONS FOR THE INDIVIDUAL AND STD TRANSMISSION IN A POPULATION 354-73
(Springer US Ed. 2006).
40 Douglas T. Fleming & Judith N. Wasserheit, From Epidemiological Synetr to Public Health Poky
and Practice: The Contribution of Other Sexual# Transmitted Diseases to Sexual Transmission of HI"
Infection, 75 SEXUALLY TRANSMITTED INFECTIONS 3 (1999).
41 Sarah Hawkes, et al., Partner Notificaion for the Control of Sexual# Transmitted Infections, 327 BRIT.
MED.J. 633 (2003).
42 See Hodge & Gostin, supra note 13.
43 Gostin & Hodge, supra note 6.
4James G. Hodge, Jr., Partner Notification, in ENCYCLOPEDIA OF PRIVACY (William G. Staples,
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recently labeled, partner counseling and referral services 45 ) were initially developed to
control the spread of syphilis and later became widely recommended for gonorrhea and
chlamydia. 46 These practices have not been very effective, however, in assuring
notification and treatment of index patients' sex partners, particularly in urban areas with
high rates of STDs.47 As a result, partner treatment is rarely assured and reinfection and
further spread are common. 48 Faced with the lack of sufficient public health resources
to support provider-led notification and the ineffectiveness of patient-led notification,
public health officials have sought innovative approaches to control the spread of
bacterial STDs like chlamydia and gonorrhea. Increasingly, such strategies have included
EPT. 49
B. Epidemiologic Evidence Supporting EPT
Health care practitioners administering EPT give the index patients antibiotics
(often coupled with information about STD risks and where to find testing providers) to
deliver directly to their sexual partners. No independent clinical assessment of the
patient's partners is performed, although it is encouraged. Numerous studies have
found reduced re-infection rates among patients in EPT programs compared to those
who have not participated in such programs.5 0 In four randomized control trials
assessing the frequency of persistent and recurrent infection following EPT, compared
to standard partner management for gonorrhea, chlamydial infection, or trichomoniasis,
ed., Greenwood Publishing Group 2005).
45 See Hodge & Gostin, supra note 13.
46 See CDC, Program Operations Guidance: Partner Serices (2000), availabk at http://www.cdc.gov/
std/program/partners.pdf (last visited Apr. 1, 2008); CDC, HIV Partner Services and Referral
Sevices: Guidance (1998), avalable at http://www.cdc.gov/hiv/resources/guidelines/pcrs/pdf/
pcrs.pdf (last visited Apr. 1, 2008).
47 In the hardest hit regions, public health departments are able to provide partner-notification
services for less than 20% of patients with gonorrhea or chlamydial infection. Matthew R.
Golden, et al., Partner Notification for HIV and STD in the United States: Low Coverage for Gonorrhea,
Cblamydial Infection, and HIV, 30 SEXUALLY TRANSMITTED DISEASES 490 (2003).
48 Matthew R. Golden, et al., Effect of Expedited Treatment of Sex Partners on Recurrent or Persistent
Gonorrhea or ChlamydialInfection, 352 NEw ENG. J. MED. 676 (2005).
49 Institute of Medicine, THE HIDDEN EPIDEMIC: CONFRONTING SEXUALLY TRANSMITTED
DISEASES (National Academies Press 1997).
50 Kristina Ramstedt, et al., Contact Tracing in the Control of Genital Chlamydia Trachomatis Infection,
2 INT'L J. STD AIDS 116, 118 (1991). See also Patricia Kissinger, et al., Effectiveness of Patint
Devered Partner Medication for Preventing Recurrent Chlamydia Trachomatis, 74 SEXUALLY
TRANSMTrED INFECTIONS 331, 331, 333 (1998); Fred Nuwaha, et al., Efficagy ofpaient-Deivered
Partner Medication in the Treatment of Sexual Partners in Uganda, 28 SEXUALLY TRANSMITTED
DISEASES 105, 105, 109-10 (2001).
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the results varied by disease and gender, but were otherwise largely consistent.
Chiamydial reinfection among index patients was reduced by approximately 20%
through EPT and gonorrhea reinfection was reduced by nearly 50%, with reinfection
rates typically lower for men than for women.51 Follow-up interviews of participants in
these studies indicated that EPT resulted in equivalent or increased partner notification
rates and consistently increased treatment rates for both diseases.52 EPT was also
associated with lower frequencies of individual behaviors that would risk re-infection,
including sexual re-exposure to untreated partners and unprotected sex with new
partners. 53 Cost effectiveness studies have suggested that EPT may reduce the net costs
of complications from chlamydia by about 50%.54 These studies demonstrate that EPT
has the potential to increase treatment of index patients' sex partners and reduce re-
infection rates among index patients, thus decreasing morbidity and health care costs
associated with gonorrhea and chlamydia.55
The benefits of EPT for reducing the public health burden of re-infection with
chlamydia and gonorrhea and the associated increased risk of complications correspond
to relatively small risks to partners receiving patient-delivered medications.56 Because
individuals who receive treatment through EPT are not clinically evaluated, there is a
risk that complications from the STD for which they are receiving treatment or co-
infection with other STDs, such as HIV, might be missed.57 For example, if a female
partner has already developed pelvic inflammatory disease, the single dose of antibiotics
delivered by the index patient may be insufficient to fully treat her condition. 58 Lack of
clinical evaluation may also represent a missed opportunity for education on risk
reduction. Concerns about adverse reactions to the antibiotics used in EPT also arise.
51 See Golden, supra note 47, at 494-95. See also Patricia Kissinger, et al., Paient-Deivered Partner
Treatment for Male Urethtriis: A Randomied, Controlkd Tria4 41 CLINICAL INFECTIOUS DISEASES
623, 628 (2005), available at http://www.joumals.uchicago.edu/doi/pdf/10.1086/432476 (last
visited Apr. 1, 2008); Schillinger, et al., Patent-Deivered Partner Treatment with Avjthromcdn to Prevent
Repeated Chlamydia trachomatis Infection Among Women, 30 SEXUALLY TRANSMITTED DISEASES
49, 49 (2003).
52 Kissinger, supra note 51, at 628.
53 See Golden, spra note 47, at 494-95; see also Kissinger, et al., spra note 50, at 331; Ramstedt,
supra note 50, at 118.
54 Maarten J. Postma, et al., Cost-Efftiveness of Partner Pharmacotherapy in Screening Women for
Ayrptomaic Infection with Chlanoydia Trachomatis, 4 VALUE HEALTH 266, 271 (2001).
55 Id. at 272.
56 See Hodge & Gostin, supra note 13, at 45-46; see also Kissinger, et al., supra note 50, at 333.
57 William M. Geisler, Management of Uncomplicated Chlamytdia Ttrachomatis Infections in Adolescents and
Adults: Evidence Reviewed for the 2006 Centers for Disease Control and Prevention Sexual# Transmitted
Diseases Treatment Guidelines, 44 CLINICAL INFECTIOUS DISEASES S77, S81 (2007).
58 Id.
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Serious adverse reactions, toxicity, or allergic reactions can occur with the antibiotic
regimens commonly used for treatment of gonorrhea and chlamydia (e.g.,
fluoroquinolones, azithromycin, and cephalosporins), but they are rare, occurring in less
than 2% of patients.5 9
C. Use of EPT in Treatment Guidelines and Practice
Multiple surveys of primary care providers suggest that many have already used
EPT for patients with gonorrhea and chlamydia. 60 Overall, about half of U.S. physicians
who treat chlamydia and gonorrhea reported that they have used EPT, but few said that
they use it most of the time. Based on these data, CDC researchers estimate that only
about 8-14% of gonorrhea diagnoses and about 13-20% of chlamydia diagnoses involve
the use of EPT.61
In 2006, after evaluating numerous studies demonstrating the success of EPT as
a public health measure and weighing the potential benefits against the potential risks,
CDC recommended the national practice of EPT for chlamydia and gonorrhea under
certain circumstances. 62 CDC guidelines state, for example, that male patients should be
given written materials on pelvic inflammatory disease to pass along to their female
partners. Existing data do not support the use of EPT for trichomoniasis or syphilis in
any populations, or for gonorrhea or chlamydia infection among men who have sex with
men (MSM). 63 CDC was hesitant to recommend the use of EPT for MSM due to
59 See, e.g., Zmax (azithromycin), in PHYSICIANS' DESK REFERENCE 2583-86, 2585-86 (Thomson
Healthcare, 616t ed. 2007); Suprax (cefixime), in PHYSICIANS' DESK REFERENCE 1843-46, 1845
(Thomson Healthcare, 618t ed. 2007); Vantin (cefpodoxime proxetil), in PHYSICIANS' DESK
REFERENCE 2645-49, 2647 (Thomson Healthcare, 611t ed. 2007); Cipro (ciprofloxacin), in
PHYSICIANS' DESK REFERENCE 2977-84, 2981 (Thomson Healthcare, 61st ed. 2007).
60 Matthew Hogben, et al., Patient-Deivered Partner Therapy for Sexual# Transmitted Diseases as Practiced
by U.S. Physidans, 32 SEXUALLY TRANSMITTED DISEASES 101, 101-04 (2005); Matthew R.
Golden, et al., Partner Noficadon for Chlarydial Infections Among Private Sector Clinidans in Seattle-King
County: A Clinidan and Patient Survqy, 26 SEXUALLY TRANSMITTED DISEASES 543, 546 (1999);
Linda M. Niccolai & Diana M. Winston, Physicians' Opinions on Partner Management for Nonviral
Sexual# Transmitted Infections, 28 AM. J. PREVENTATIVE MED. 229, 230 (2005); Meighan E. Rogers,
et al., Paient-Deivered Partner Treatment and Other Partner Management Strategies for Sexualy Transmitted
Diseases Used by New York Ci Healthcare Providers, 34 SEXUALLY TRANSMITTED DISEASES 88, 88-
91 (2007); Laura J. Packel, et aL, Patent-Deivered Partner Therapy for Chlamydia Infections: Attitudes
and Pratices of Cakfornia Physidans and Nurse Practitioners, 33 SEXUALLY TRANSMTTED DISEASES
458, 459-61 (2006).
61 See Hogben, supra note 60, at 102.
62 CDC STD Disease Treatment Guidelines, supra note 12, at 40, 45.
63 Id.
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heightened concern over the risk of missing an opportunity to screen partners for HIV
based on observed rates of comorbid HIV infection among MSM. 64 In many regions,
however, local epidemiologic data may provide sufficient reassurance that EPT is safe
for the MSM population. 65
III. Overview of Legal Issues Concerning EPT
Although many reasons underlie the inconsistent use of EPT across the United
States, a contributing factor is the perception that the practice is unlawful. In a 2005
survey of members of state medical and pharmaceutical boards, 88% of respondents
reported that they perceived EPT as illegal or of "uncertain" legality. 66 In some cases
survey respondents from the same jurisdiction differed in their opinions as to the legality
of EPT.67 In this Part, we seek to clarify the types of legal issues that may contribute to
these perceptions by examining laws that affect whether EPT is permissible, including
(1) licensing laws for health care practitioners, (2) public health treatment requirements
and guidelines for STDs, and (3) potential liability themes. We also discuss laws
affecting the implementation of EPT, including (1) laws regulating dispensation of
prescription drugs, (2) state labeling requirements for prescriptions, and (3) insurance
and reimbursement policies.
A. Laws Affecting Permissibility of EPT
Licensing of health care practitioners and pharmacists.
In the majority of states in which EPT is not explicitly authorized via statute or
regulation, a primary legal issue is whether health care practitioners will be subject to
discipline by state licensing boards for providing a prescription to a person who is not
their patient (the patient's partner) and whom the practitioner has not previously
evaluated.68 Providing access to prescription medications to persons with whom a
clinician has not established a professional relationship with or examined is statutorily
and/or administratively barred in some states. 69 These laws are designed to protect
64 Id. See also Joanne Stekler, et aL, Concurttnt Sexual# Transmitted Infections in Sex Partners of Index
Patients with Bacteial STIs: Implications for Patient-Deivered Partner Therapy, 40 CLINICAL INFECTIOUS
DISEASES 787, 788 (2005).
65 Hodge et al., supra note 17, at 242.
66 Golden et al., supra note 16, at 113.
67 Id.
68 See id. at 114.
69 See e.g., ALA. ADMIN. CODE r. 540-X-9.11 (2000); ARIZ. REV. STAT. ANN. § 32-1401(27)(ss)
(2006); 844 IND. ADMIN. CODE 5-4-1(b) (2003); LA. ADMIN. CODE tit. 46, Pt. LIII, § 2515
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patients and the public from potentially unscrupulous actors who may seek to distribute
potentially harmful prescription drugs without proper clinical evaluations.70 Sanctions
for such misconduct can include censure, fines, suspension, or revocation of a
practitioner's license. 71
In addition, practitioners who use EPT may be subject to discipline for violating
licensing regulations that limit the delegation of prescription drug distribution to
licensed practitioners. 72  Because EPT may involve delegating distribution of
prescription drugs to an unlicensed person (the patient), licensed practitioners may
violate such laws when participating in EPT.73 These laws reflect the principle that
individuals should not have access to medications they do not need or that could be
harmful if taken improperly. This concern is also reflected in regulations limiting the
distribution of prescription drugs over the Internet or via telemedical encounters. 74
Complicating matters further, different types of practitioners such as physicians,
nurses, physicians' assistants, and pharmacists are often regulated under separate
licensing laws. 75 Thus, even within a single jurisdiction, different practitioners may be
restricted from practicing EPT depending on their licensing standards. 76 For example,
(2004); Mo. CODE REGS. ANN. tit. 20, § 2150-5.020 (2006); OKLA. STAT. tit. 59, §§ 509, 637
(2004); S.C. CODE ANN. REGS. 81-28 (2001); W. VA. CODE R. § 11-1A-12(12.2)(k) (2007).
70 See e.g., ALA. ADMIN. CODE r. 540-X-9.11 (2000); ARIZ. REV. STAT. ANN. § 32-1401(27)(ss)
(2006); 844 IND. ADMIN. CODE 5-4-1(b) (2003); LA. ADMIN. CODE tit. 46, Pt. LIII, 5 2515
(2004); MO. CODE REGS. ANN. tit. 20, S 2150-5.020 (2006); OKLA. STAT. tit. 59, 5§ 509, 637
(2004); S.C. CODE ANN. REGS. 81-28 (2001); W. VA. CODE R. § 1 1-lA-12(12.2)(k) (2007).
71 See e.g., ALA. ADMIN. CODE r. 540-X-9.11 (2000); ARIZ. REV. STAT. ANN. 5 32-1401(27)(ss)
(2006); 844 IND. ADMIN. CODE 5-4-1(b) (2003); LA. ADMIN. CODE tit. 46, Pt. LIII, § 2515
(2004); Mo. CODE REGS. ANN. tit. 20, § 2150-5.020 (2006); OKLA. STAT. tit. 59, §5 509, 637
(2004); S.C. CODE ANN. REGS. 81-28 (2001); W. VA. CODE R. § 11-lA-12(12.2)(k) (2007).
72 See CONN. GEN. STAT. § 2 0-14e(c) (1999); see also IDAHO ADMIN. CODE r. 27.01.01.184 (2005);
88 MD. Op. Arr'y GEN. 88 (2003).
73 See CONN. GEN. STAT. § 20-14e(c) (1999); accord IDAHO ADMIN. CODE r. 27.01.01.184 (2005);
see also 88 MD. OP. Anrry GEN. 88 (2003).
74 See, e.g., ALASKA ADMIN. CODE tit. 12, 5 40.967 (2000); FLA. ADMIN. CODE ANN. r. 64B8-
9.014 (2003); OKLA. ADMIN. CODE § 535:15-3-13 (2005).
71 See ALA. ADMIN. CODE r. 610-X-5.11, 610-X-5.22 (2007) (providing that nurses and physician
assistants may not prescribe for non-patients of supervising physician); OHIO REV. CODE ANN. §
4730.21 (LexisNexis 2008) (providing that physician assistants may not provide treatment for
new patients without prior physician evaluation).
76 See ALA. ADMIN. CODE r. 610-X-5.11, 610-X-5.22 (2006) (providing that nurses and physician
assistants may not prescribe for non-patients of supervising physician); OHIO REV. CODE ANN. §
4730.21 (providing that physician assistants may not provide treatment for new patients without
prior physician evaluation).
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in a few states, pharmacists are subject to disciplinary action by the state licensing
authority if they dispense a prescription and know, or have reason to know, that the
prescription is not supported by a physician-patient relationship or prior evaluation.7
These laws may prevent pharmacists from participating in EPT even if physicians are
permitted to do so, thus reducing the likelihood that the partner will ultimately receive
the prescription. 78 Controlled substance laws and regulations that place additional
requirements on the distribution of certain drugs, however, do not apply to EPT
because antibiotics used to treat chlamydia and gonorrhea are not controlled substances.
Most states' laws do not specify whether a prescription issued outside the
physician-patient relationship or prior evaluation is a per se instance of physician
misconduct. The question becomes whether such practice falls under a more
generalized bar against unprofessional medical practice. To address this issue, a
licensing authority typically examines the facts of the particular case to determine
whether the practitioner deviated from norms of acceptable medical practice. 79 The
outcome may depend on whether the decision-making body defines the scope of the
practice broadly (applying to any prescription given to a non-patient not previously
examined) or narrowly (acceptable when limited to conditions such as chlamydia or
gonorrhea, for which EPT is supported by clinical and public health research), 0 A
resulting tension for practitioners and medical boards arises: while as a general matter
providing any prescription without a prior evaluation or physician-patient relationship is
impermissible, the administration of EPT in the limited circumstances for which it has
been studied could be deemed good medical and public health practice.81
77 See FLA. STAT. § 465.023; MICH. CoMP. LAWS ANN. § 333.17751; OHIO ADMIN. CODE 4729:5-
30(A); OKLA. ADMIN. CODE 535:15-3-13(d); S.C. CODE ANN. S 40-43-86; TEx. Occ. CODE
ANN. § 291.104; W. VA. CODE § 30-5-3.
78 See FLA. STAT. S 465.023.
79 See Carloni v. De Buono, 245 A.D.2d 970, 972 (N.Y. App. Div. 1997); Balmir v. De Buono,
237 A.D.2d 648, 649 (N.Y. App. Div. 1997); Jones v. North Dakota. State Bd. of Med. Exam'rs.,
691 N.W.2d 251 (N.D. 2005); Reed v. State Med. Bd. of Ohio, 833 N.E.2d 814 (Ohio Ct. App.
2005); Royder v. State Med. Bd. of Ohio, 2002 WL 31867888 (Ohio Ct. App. 2002); State ex rel.
Okla. Bd. Of Med. Licensure & Supervision v. Litchfield, 103 P.3d 1111 (Okla. Civ. App. 2004);
State v. Ray, 848 P.2d 46 (Okla. Civ. App. 1992); Gale v. State Bd. of Med. Exam'rs., 320 S.E.2d
35 (S.C. Ct. App. 1984).
80 Cf State ex rel. Okla. Bd. Of Med. Licensure & Supervision v. Litchfield, 103 P.3d 1111, 1117
(Okla. Civ. App. 2004) (upholding sanctions against physician who provided prescriptions
without establishing physician-patient relationship).
81 See id. But see CDC STD Disease Treatment Guidelines, supra note 12, at 68.
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Public health treatment requirements concerning STDs.
Health care practitioners practicing EPT may also run afoul of state public
health laws. State public health agencies may promulgate regulations regarding the
treatment of STDs that require practitioners to take certain actions concerning the
treatment of persons with STDs. Violations of these regulations may carry civil fines or
criminal misdemeanor penalties. Some states, for example, require examination of all
persons seeking treatment for STDs 82 or allow treatment only if the person is found to
have the condition. 83 In addition, most states require physicians to report all cases of
STDs to public health authorities. Administering EPT may compromise such reporting
for the patient's partners whose identities and diagnoses may be unknown. In these
states, EPT may conflict with the public health authorities' legally-prescribed protocols
for the treatment of STDs, even though EPT is a proven way to prevent the spread of
STDs.
Public health regulations supporting EPT
Alternatively, state public health regulations may support EPT even if they do
not specifically authorize it. A state public health authority may allow non-patient
specific (a/k/a "standing order' treatment protocols for certain STDs.84 For example,
in Utah, a physician may write a standing order prescription that does not include a
patient's name or the date for the treatment of STDs. 85 The prescription is then filled
out and provided to the patient by a nurse.86 This type of protocol may facilitate
anonymous treatment of STDs or treatment of persons whom the physician has not
examined, or with whom the physician has not established a physician-patient
relationship.
More commonly, states' regulations incorporate by reference the
recommendations of published treatment guidelines such as CDC's STD Treatment
Prevention Guidelines (which currently recommend EPT) or the American Public Health
Association's (APHA) Control of Communicable Diseases Manual 8 7 Nevada, for example,
82 See ILL. ADMIN. CODE tit. 77 § 693.50(a)(3); 902 KY. ADMIN. REGS. 2:080; VT. STAT. ANN. tit.
18, §1093.
83 See IOWA CODE ANN. 139A.34; WASH. ADMIN. CODE § 246-100-203.
84 See MINN. STAT. ANN. % 148.235,151.37; UTAH CODE ANN. § 58-17b-620.
85 UTAH CODE ANN. § 58-17b-620(3).
86 Id. at § 58-17b-620(3)(b).
87 CDC STD Disease Treatment Guidelines, supra note 12; AM. PUB. HEALTH ASS'N., CONTROL OF
COMMUNICABLE DISEASE MANUAL (David L. Heymann ed., 18th ed. 2004). For states that
incorporate one or both of these guidelines by reference, see ALASKA ADMIN. CODE tit. 7, 5
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requires health care providers to treat chlamydia and gonorrhea pursuant to the CDC's
Guidelines.88 Provided that these guidelines recommend EPT for certain conditions,
they would be incorporated into the state's regulations as an accepted treatment practice.
To the extent that medical or other licensing boards look to these guidelines for
guidance, the practice of EPT may increasingly be viewed as within the standards of
acceptable medical practice for the treatment of gonorrhea and chlamydia.
Even in states where laws prohibit practitioners from providing prescription
drugs to patients who the practitioner has not physically examined, the adopted
treatment guidelines may potentially allow EPT by creating a limited exception to the
general laws barring provision of prescription drugs to non-patients or persons not yet
evaluated. 89 Other states allow public health authorities to establish treatment standards
for STDs and other communicable diseases that are consistent with medical and
epidemiologic evidence, which may lead to the adoption of EPT as acceptable treatment
practice for gonorrhea and chlamydia.90
Liabi60.
Potential liability of health care practitioners and patients is a pervasive concern
under EPT. Patients may fear criminal liability for delivering drugs to their partners via
EPT. Some jurisdictions make it illegal for anyone to sell, distribute, or dispense
prescription drugs for the treatment of an STD except pursuant to a valid prescription
by an authorized health care practitioner.91 These laws may expose patients to criminal
misdemeanor sanctions if their acts of giving medications to partners to treat STDs are
considered distribution of drugs in the absence of a valid prescription. These provisions
may be especially problematic if the clinician's original prescription refers only to the
patient, rather than the partner, as the ultimate user.
27.010; 007-26-001; ARK. CODE R. § I; D.C. MUN. REG. tit. 22, §§ 202.8; 410 IND. ADMIN. CODE
1-2.3-59; 1-2.3-67; 10-155-258; ME. CODE R. § 5; MD. CODE REGS. §§ 10.06.01.01, 10.06.01.07;
MO. CODE REGS. ANN. tit. 19, § 20-20.040; MONT. ADMIN. R. 37.114.515, 37.114.530; 173 NEB.
ADMIN. CODE § 1-006; NEV. ADMIN. CODE §§ 441A.200, 441A.490, 441A.540; 10A N.C.
ADMIN. CODE 41A.0201, 41A.0204; S.C. CODE. ANN. REGS. 61-20; S.D. ADMIN. R. 44:20:03:01;
UTAH ADMIN. CODE r. 386-702-12; 12 VA. ADMIN. CODE § 5-90-100; WASH. ADMIN. CODE
246-100-036; WIS. ADMIN. CODE [HFS] S 145.22.
88 NEV. ADMIN. CODE §§ 441A.490, 540 (1989).
89 See 844 IND. ADMIN. CODE 5-4-1 (b); 410 IND. ADMIN. CODE 1-2.3-59; 1-2.3-67.
90 See ALA. CODE § 420-4-1.05; ME. REV. STAT. ANN. tit. 22, S 807; MD. CODE BEGS.
10.06.01.06; N.Y. COMP. CODES R. & REGS. tit. 10, § 23.2; 12 VA. ADMIN. CODE § 5-90-100.
91 See ALA. CODE § 22-11A-21; MD. CODE. ANN. CRiM. LAW § 10-103; OKLA. STAT. tit. 59 § 1-
521.
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Practitioners may also be concerned about their potential criminal liability as an
accessory to the patient's criminal acts. However, physicians are more likely to be
concerned primarily with the potential to be sued by patients or their partners for
injuries resulting from EPT on medical malpractice grounds. 92 Claims of medical
malpractice against physicians using EPT in cases of chlamydia and gonorrhea are
theoretically possible, but highly unlikely for a very simple reason: the risks of significant
harm to partners are virtually none. To establish a malpractice claim the partner must be
injured as a result of receiving and taking an unauthorized prescription without prior
examination. Because the risk of adverse reactions to the type of antibiotics used in
EPT is low and can be managed with reasonable precautions, the threat of medical
malpractice, though theoretically possible, is comparably low. We have not uncovered a
single reported case of a clinician being sued for malpractice by anyone, whether patient
or partner, solely for harms resulting from taking antibiotics for STDs like chlamydia
and gonorrhea. The few cases that relate to EPT usually involve court review of a board
decision to revoke a physician's license, but not medical malpractice. 93
B. Laws Affecting Implementation of EPT
Other laws, including regulations of prescription drug dispensation, labeling,
and insurance and reimbursement policies, may not bar EPT entirely within a state but
rather affect its implementation.
92 See Packel et at., supra note 60.
93 See Jones v. North Dakota State Bd. of Med. Examrs., 691 N.W.2d 251, 258 (N.D. 2005)
(upholding revocation of physician's license for prescribing over the Internet without prior
examination or physician-patient relationship); Reed v. State Med. Bd. of Ohio, 833 N.E.2d 814,
825 n.4 (Ohio Ct. App. 2005) (upholding revocation of physician's license when she prescribed
extra doses of antibiotic to a patient who insisted on giving extra doses to her husband); Royder
v. State Med. Bd. of Ohio, 2002 WL 31867888 (Ohio Ct. App. 2002) (upholding revocation of
physician's license for failing to evaluate new patients before giving a prescription, and instead
delegating to a physician assistant); State ex reL Oklahoma Bd. of Med. Licensure and Supervision
v. Litchfield, 103 P.3d 1111, 1114-15, 1117 (Okla. Civ. App. 2004) (upholding suspension of
physician's license and finding of misconduct when physician prescribed to patients without
establishing a physician-patient relationship or prior examination); Carloni v. De Buono, 245
A.D.2d 970, 972 (N.Y. App. Div. 1997) (upholding revocation of physician's license for
misconduct, including issuing a prescription without prior examination); Balmir v. De Buono,
237 A.D.2d 648, 649 (N.Y. App. Div. 1997) (upholding revocation of physician's license for
refilling prescriptions that were inconsistent with physical finding where patients produced empty
medication bottles); State v. Ray, 848 P.2d 46, 47 (Okla. Civ. App. 1992) (upholding disciplinary
action against physician for filling prescription without establishing "doctor/patient relationship
and/or examination"); Gale v. State Bd. of Med. Exam'rs, 320 S.E.2d 35, 38 (S.C. Ct. App. 1984)
(upholding revocation of physician's license when physician wrote prescriptions outside of
physician-patient relationship).
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Dispensation ofpresrition drugs.
Laws that limit dispensation of prescription drugs by practitioners to their
patients (directly giving patients prescription drugs as opposed to giving the patient a
prescription order for drugs) may prevent practitioners from utilizing EPT because to
do so may involve dispensing prescription drugs to a person who is not the
practitioner's patient.94 In Michigan, for example, a prescribing practitioner can only
dispense prescription drugs to the practitioner's own patients, but the law is silent about
whether a practitioner canpresaibe for persons other than his or her own patients. 95
Although a practitioner may still practice EPT by writing a prescription for the
patient's partner to be dispensed at a pharmacy, the practitioner would not have the
option of dispensing an "extra dose" directly to the patient to give to his or her partner.
In other words, a clinician could not simply provide the patient with a double dosage of
antibiotics with instructions to provide one dose to the partner. Instead, the clinician
would have to write a distinct prescription for the partner. This would require patients
to reveal their partners' identities, raising health information privacy concerns.
Similarly, pharmacy regulations that limit dispensation of prescription drugs to
the "ultimate user" could interfere with the practice of EPT.96  Under such
requirements, a pharmacist would not be allowed to knowingly give an extra dose to the
patient for his or her partner (even if the clinician authorized it via prescription). The
partner could come in to receive his or her own prescription, but the separate trip to the
pharmacy may lower the number of partners obtaining treatment for the STD, thus
reducing the efficacy of EPT.
Patient identification requirements for presptions.
Laws requiring prescription orders or labels to identify the person for whom the
prescription is intended may also affect implementation of EPT. In Montana, for
example, a prescription must bear the patient's name and address. 97 If identifying
information is required, a physician may not be legally permitted to provide a blank
prescription or an "extra dose" for the patient to deliver to the partner. Instead, a
94 See ALA. ADMIN. CODE r. 610-X-5.11, 610-X-5.22; MD. CODE ANN., HEALTH-Occ. § 12-102;
MICH. COMP. LAWS ANN. § 333.17745.
91 MICH. COMP. LAWS ANN. § 333.17745.
96 See ARK. CODE ANN. S 17-92-505; HAW. REV. STAT. § 328-16(b)(3); KAN. STAT. ANN. § 65-
162 6(g); 247 MASS. CODE REGS. 2.00 (2008).
97 MONT. CODE. ANN. § 37-7-101.
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prescription may have to be made out in the partner's name, again raising privacy
concerns and logistical challenges. Furthermore, additional informational requirements
about the partner, such as address or birth date, may hinder the ability of a practitioner
to write a valid prescription for the partner if the patient does not know or is unwilling
to share such information about the partner. This raises multiple legal issues, primarily
those discussed previously regarding the legality of prescribing to a person with whom
the practitioner does not have a relationship and whom the practitioner has not
evaluated.
Insurance and rembursement.
Finally, insurance and reimbursement policies may affect the feasibility of EPT.
Who should pay for the extra dose of antibiotics distributed to the patient for the
partner? Should a patient's health insurance provider cover the costs of two doses, even
though the partner (who may not be insured by the same provider or at all) is the
recipient of the extra dose? Denying payment for these medications, while antithetical
to public health promotion, may be routine policy for insurance providers who are not
obligated to pay for the treatment of anyone other than the insured, even where
nonpayment may increase future costs for the insured due to reinfection or
complications.98
IV. Comprehensive Assessment of the Legal Status of EPT
Against this backdrop of perceived and actual legal issues confronting the
practice of EPT in many states, the Center and CDC analyzed laws and policies across all
states, the District of Columbia, and Puerto Rico, to assess the legality of EPT. Key
legal provisions and policies were examined to respond specifically to a central inquiry:
whether a physidan or other health care provider may provide a prescription for a non-contmled
substance to a patient's partner, without prior evaluation of the partner, for the purposes of treating the
partnerfor specific STDs. The main presumption underlying our assessment and findings is
the absence of a pre-existing physician-patient relationship or physical examination
between the health care provider and the patient's partner.
A. Methodology
The Centeis assessment entailed an examination of pertinent laws in each
jurisdiction to ascertain whether they (1) expressly or implicitly approve of or reject EPT
98 Hodge et al., supra note 17.
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or like practices, or (2) support the practice of EPT where laws, coupled with policy
directives, potentially allow for its implementation. As discussed in Part III.B below,
through careful interpretation of the legal environment, we classified each jurisdiction as
to whether it permits, potentially allows, or prohibits EPT. While our assessment does
not comprehensively analyze all laws that may be implicated by EPT in each jurisdiction
and should not be considered as providing specific legal advice in any jurisdiction, we
address the key legal issues discussed in Part III above.
First, we systematically reviewed existing statutes and regulations that expressly
authorized (or prohibited) EPT or similar practices. Relevant provisions were found in
laws governing the establishment of the physician-patient relationship, defining
clinicians' authority to prescribe and delegate treatment, and setting forth requirements
for the treatment of communicable diseases. We also examined introduced bills that
would expressly authorize EPT.
The next source of law we examined were judicial decisions that implicate the
legality of EPT. While there have been no reported cases specifically concerning EPT,
relevant cases in a number of jurisdictions have addressed whether providers may be
sanctioned for prescribing medications for non-patients without prior examination. In
Reed v. State Medical Board of Ohio,99 for example, an Ohio appellate court upheld the
medical board's revocation of a physician's license because the physician, among other
offenses, prescribed a "triple dose of the antibiotic amoxicillin to a patient who insisted
upon giving the extra doses to her husband.100 This act was considered to be contrary
to the accepted standards of the medical profession. Other cases, while relevant, are not
dispositive regarding the legality of EPT because they address the prescription of
controlled substances, which, as noted earlier, are subject to separate, additional
restrictions beyond those applicable to the antibiotics used for EPT.10 1
We also looked closely at state administrative opinions, including
recommendations by medical and pharmacy boards and opinions by Attorneys General,
because of the significant weight that courts and decision-makers give these opinions in
interpreting statutes and regulations. Where statutes or regulations are ambiguous or
silent about the legal status of EPT, these opinions shed light on whether EPT
comports with the established standard of care in a jurisdiction. For example, Iowa's
99 833 N.E.2d 814 (Ohio Ct. App. 2005).
100 Id. at 825, N. 4.
"'" See State ex rd/ Oklahoma Bd. of Med. Licensure and Supervision v. Litchfield, 103 P.3d 1111,
1114-15, 1117 (Okla. Civ. App. 2004) (upholding findings of misconduct when anesthesiologist
prescribed controlled substances without examination or physician-patient relationship).
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Attorney General addressed whether a physician had to be present while his agent
administered a prescription drug, opining that supervision of the agent under the Iowa
Pharmacy Practice Act does not necessarily require the physical presence of the
physician. 102 The Iowa Attorney General felt that this practice was consistent with the
proposed rules of the Iowa Board of Pharmacy Examiners and the Board of Medical
Examiners.1 03 Still, the Iowa Attorney General cautioned that it was not issuing a
conclusive determination as to what qualifications an agent must have to administer
prescription drugs.' 04 Consequently, it implicitly left open the possibility that patients
may deliver prescriptions to their sexual partners via EPT without the physician being
present.
B. National Legal Assessment of EPT
Based on the comprehensive legal assessment discussed above, the legality of
EPT in each jurisdiction was classified into three categories: (1) EPT is permissible, (2)
EPT is potentially allowable, and (3) EPT is prohibited. Figure 1, below, illustrates
these findings for each jurisdiction.
LI UT is Permisible
EPT is Potetilly Allowable
ET is Prohibited * OD- flrmo
'
02 STATE OF IOWA, OFFICE OF THE ATTORNEY GEN., No. 00-11-7, AUTHORITY OF
PHARMACIST TO ADMINISTER PRESCRIPTION DRUGS PURSUANT TO WRITTEN PROTOCOL OF
PHYSICIAN (2000), 2000 IOWA AG LEXIS 44.
103 Id. at 8-10.
104 Id. at 12.
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1. EPT is Permissible
Any jurisdiction in which laws expressly authorize the implementation of EPT
for the treatment of STDs was designated as "EPT is permissible." Among the twelve
total jurisdictions in which EPT was deemed legally permissible, four (CA, MD
(Baltimore), MN, and TN) feature express statutory language permitting its
implementation. 105 In California, for example, a physician who diagnoses chlamydia,
gonorrhea, or other sexually transmitted infections, "may prescribe, dispense, furnish, or
otherwise provide prescription antibiotic drugs to that patient's sexual partner or
partners without examination of that patient's partner or partners."' 106 Similarly, in
Tennessee, a physician may "[p]rovide to the treated patient non-named signed
prescriptions for, or dispense to the patient, the appropriate quantity and strength of
azithromycin [for the treatment of chlamydia] sufficient to provide curative freatmentfor the
total number of unnamed 'partners" [of the patient]. .."107 In such instances, the
authorization of EPT or like practices is limited to the treatment of specific diseases
(e.g., chlamydia or gonorrhea) under particular circumstances. However, its legality in
these states is virtually unquestionable.
In the absence of any express statutory or regulatory authorization, EPT was
also deemed permissible in eight jurisdictions in which (1) advisory opinions recommend
its use, or (2) guidelines supporting its use were incorporated by reference via regulations
governing the treatment of STDs. While administrative board opinions are not
themselves binding legal precedent, they are afforded significant weight and judicial
deference. 08 Moreover, advisory opinions prescribe or prohibit practices consistent
with the Boards' own view of the prevailing standard of care requirements, which they
apply to licensees in disciplinary proceedings. 10 9 In Colorado, for example, there were
no statutes or regulations expressly authorizing or precluding EPT or like practices.
However, the Colorado Medical Board of Examiners opined that "[tireating partners of
patients with sexually transmitted infections is generally considered acceptable and
desirable if the partner will not seek treatment from his or her primary healthcare
provider."" 0 In Nevada, regulations automatically recognize the most current version
105 CAL. HEALTH & SAFETY CODE ] 120582 (West 2007); MD. CODE ANN., HEALTH-GEN. §
18-214.1 (West 2007); MINN. STAT. §§ 148.235, 151.37 (2008); TENN. COMP. R. & REGS., 1050-2-
.13(9)(d) (2007); TENN. COMP. R. & REGS. 0880-2-.14 (2007).
106 CAL. HEALTH & SAFETY CODE § 120582 (West 2007).
107 TENN. COMP. R. & REGS. 1050-2-.13(9)(d) (2007) (emphasis added).
108 See Legal Status of Expedited Partner Therapy, supra note 1.
109 Id.
110 COLO. STATE BD. OF MED. EXAM'RS, APPROPRIATENESS OF TREATING PARTNERS OF
PATIENTS WITH SEXUALLY TRANSMITFED INFECTIONS, POL'Y NUMBER 40-10 (2001), available at
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of CDC's STD Treatment Guidelines as the appropriate standard of care for the treatment
of STDs."' Moreover, Nevada's regulations mandate adherence to the guidelines for
the treatment of chlamydia and gonorrhea.112 Provided that other laws do not preclude
the practice of EPT, these opinions, or the incorporation by reference of modem STD
treatment guidelines, suggest a favorable legal environment in which EPT is permissible.
As discussed in the following subsection, this conclusion is distinguishable from
jurisdictions with favorable policy opinions or that incorporate the CDC guidelines by
reference against a backdrop of statutes or regulations that do not expressly support
EPT or like practices.
2. EPT is Potentialy Allowable
In jurisdictions in which laws do not expressly authorize or prohibit the practice
of EPT, its legality may be inconclusive. Subject to reasonable interpretations of law,
EPT is potentially allowable in twenty-seven jurisdictions (see Figure 1). In some states,
the applicable statutes and regulations are silent as to whether a practitioner can
prescribe antibiotics to a person who is not a patient without a prior examination.11 3 In
other states, statutes and regulations governing health care providers and pharmaceutical
requirements are ambiguous or contradictory concerning prescriptions for non-patient,
third-party consumers. Laws that do not unequivocally contemplate third-party
prescriptions may not be relied upon to support the legality of EPT. In New Jersey, for
example, the state department of health may provide antibiotics and other appropriate
drugs for the treatment and prevention of STDs. n 4 On its face, this statute allows the
health department to dispense medications to treat STDs without demarcating clear
boundaries that either expand or constrict third-party prescriptions. 1 15  However,
another New Jersey statute provides that a prescription "means a lawful order of a
practitioner for a drug, a device or a diagnostic agent for a spedfic pafient."' 11 6 This
provision requires lawful prescriptions to be issued to a specified patient, or someone
who has typically established a relationship with a health care provider and presumably
undergone a physical examination. 1 7 Because the practice of EPT involves prescribing
http://www.dora.state.co.us/Medical/policies/40-10.pdf (last visited Apr. 1, 2008).
M' NEV. ADMIN. CODE § 441A.200 (2006).
112 NEV. ADMIN. CODE 5 441A.490 (2007); NEV. ADMIN. CODE § 441A.540 (1992),
113 States whose licensing and public health laws are silent regarding the ability of practitioners to
prescribe without prior examination or physician-patient relationship include: Delaware, Georgia,
Idaho, Kansas, Mississippi, New Hampshire, and Rhode Island.
114 N.J. STAT. ANN. § 26:4-47 (West 2007).
11s See id
116 N.J. STAT. ANN § 45:14-41 (West 2006) (emphasis added).
117 See id.
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drugs to a specified patient (and a partner), it may not violate New Jersey law per se.
The legality of EPT, however, is ambiguous since neither statutory provision expressly
authorizes nor precludes third-party prescriptions for treating STDs. Consequently,
EPT is potentially allowable in New Jersey.
The ambiguity of third-party prescriptions is compounded by the effect of
pharmaceutical requirements. While a patient's sexual partners are not legally paients,
they are the persons for whom the prescriptions are intended. Some jurisdictions, such
as Massachusetts, define "dispensing" as a "physical act" of delivery to "an ultimate
user." 118 In such cases, pharmacists must presumably limit dispensation of the drug to
the partner and use the partner's name and address on the prescription label, as required
by regulations. Still, the lack of express statutory preclusions, coupled with the
introduction of a prior bill to support EPT,"1 9 suggests that the legal landscape in a state
like Massachusetts may also potentially allow EPT in practice.
Finally, as mentioned above, some states have administrative opinions favorable
to EPT or incorporate by reference treatment guidelines recommending EPT, but other
laws or regulations within the same state undermine the practice of EPT. In Indiana,
public health regulations incorporate by reference the CDC's guidelines for the
treatment of chlamydia and gonorrhea, 120 but elsewhere Indiana statutorily bars
physicians from prescribing or dispensing prescription drugs to those the physician has
never examined. 121 EPT may be allowable if the regulations incorporating the CDC
guidelines are seen as creating a narrow exception to the general statutory ban on
prescribing without prior examination.
3. EPT is Prohibited
Thirteen states expressly preclude EPT or like practices pursuant to statutes,
regulations, policies, or a combination thereof (see Figure 1). In South Carolina, for
example, "[ilt is unprofessional conduct for a physician to prescribe drugs to an
individual without first establishing a proper physician-patient relationship."' 122 In
Illinois, "if a physical examination or necessary laboratory examination has not been
performed" for the treatment of syphilis, gonorrhea, or chlamydia, health officials must
118 247 MASS. CODE REGS. 2.00 (2008)
119 S.B. 650, 183rd Gen. Court, Reg. Sess. (Mass. 2003).
120 410 IND. ADMIN. CODE 1-2.3-59 (2006); 410 IND. ADMIN. CODE 1-2.3-67 (2006).
121 844 IND. ADMIN CODE 5-4-1(b) (2003).
122 S.C. CODE ANN. REGS. § 81-28(A) (2007).
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"request that individual to report for such examination." 123  Under this statutory
mandate, sexual partners of patients with STDs must be physically examined prior to
receiving prescription treatment. 124
Legal obstacles in other jurisdictions stem from pharmaceutical requirements.
In Michigan, pharmacists can only dispense prescriptions pursuant to an existent
physician-patient relationship.125 Although a single legal provision may not amount to a
categorical denial of EPT's legality, the collective laws and policies were read as mutually
enforcing. Consequently, deference was given to the express language of existing
statutes and regulations. Where legal provisions clearly impeded the implementation of
EPT and there was an absence of other supporting laws or policies (as may exist in
jurisdictions where EPT is permissible or potentially allowable), EPT was determined to
be prohibited within that jurisdiction.
V. Evaluation of Legal and Policy Options to Facilitate EPT
Contrary to perceived illegalities suggested by Golden's survey,126 the Center's
assessment revealed that EPT is legally permissible or potentially allowable in the
majority (thirty-nine) of U.S. jurisdictions. 127 These differing conclusions may be
explained in part by the fact that the previous survey was based on non-legal opinions
proffered by physicians and pharmacists, 128 while the Center's findings stemmed from a
methodical legal assessment of relevant laws and policies within each jurisdiction. 129
There are, however, limits to the Center's analysis. Notably, legal interpretations vary
extensively. The Centers assessment has not been fully validated among public health
legal counsel, legislators, members of the judiciary, and others on a jurisdictional level.
Changes in legally-binding factors (e.g., statutory enactments, adoption of specific STD
practices) and the influence of non-binding legal sources, such as medical and pharmacy
board policies or Attorney General opinions, may instantly alter the legal environment in
each jurisdiction. Public health authorities, health care professionals, and policymakers
must weigh existing law and policy options and interpretations. Recognizing that the
legality of EPT is somewhat inconclusive (i.e. potentially allowable) in twenty-seven
jurisdictions, and likely prohibited in thirteen others, potential barriers to its national
123 ILL. ADMIN. CODE tit. 77 § 693.50(a)(3) (2008).
124 Id.
125 MICH. COMP. LAWS ANN. § 333.17751(1) (West 2008).
126 Golden et al., supra note 16, at 113.
127 See Legal Status of Expedited Partner Therapy, supra note 1.
128 Golden et al., supra note 16, at 112.
129 See Legal Status of Expedited Partner Therapy, supra note 1.
2008
JOURNAL OF HEALTH & BIOMEDICAL LAW
implementation must be addressed.
Accordingly, we proffer below a series of law and policy options designed to
facilitate the national implementation of EPT to improve the public's health. These
suggested policies include reforms to: (1) expressly endorse EPT through statutory or
regulatory enactments, facilitated by the creation of model statutory language; (2) adopt
modern, updated national treatment guidelines; (3) create exceptions to constrictive
prescription drug requirements; (4) seek increased medical or pharmaceutical board
support for EPT; and (5) support insurance payments for partners' medications
provided through EPT.
Create and enact laws that expressly endorse EPT Although we conclude
that the laws of 75% of the jurisdictions we studied permit or potentially allow the
practice of EPT, an essential theme from our analysis is the presence of contradictory
legal provisions and policy opinions in many jurisdictions. In Maine, for example, the
Board of Licensure for Medicine has opined that dispensing medications to someone
without having conducted a personal examination may constitute unprofessional
conduct. 130 Still, Maine has incorporated by reference APHA's CCD Manual' 3' and the
CDC's STD Treatment Guidelines132 for notifiable conditions, both of which may support
EPT. 133  Consequently, health care providers may find themselves torn between
adhering to a standard of care recommended by their state's disciplinary body and
following the standard adopted (by reference) by the public health authority that may be
in the best interests of their patients and the public's health. Facing the potential for
sanctions or civil liability, even if remote, many health care providers will not practice
EPT, as illustrated through the survey conducted by Golden and his colleagues.134
Statutes or other laws that explicitly allow EPT can empower health care
providers to practice without fear of sanction, liability, or other harms. Effective
legislation or regulation can also help define the scope of EPT by specifying applicable
diseases, identifying health care practitioners who may prescribe medications, dismissing
potential claims for civil liability, and expressly authorizing its use amidst ambiguous
laws or policies. In addition to the four states that have enacted laws expressly
130 Maine Board of Licensure in Medicine, Board Pofio on Intenet Preseribin$g (Nov. 12, 2002),
available at http://www.docboard.org/me/administrative/POLICIES/INTERNET_
PRESCRIBINGSECTION_%201V_GEN.doc.
131 See AM. PUB. HEALTH ASS'N., supra note 87.
132 See CDC STD Disease Treatment Guideines, supra note 12.
133 ME. REV. STAT. ANN. tit. 22 S 807 (2007).
134 Golden, et al., supra note 16, at 114.
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endorsing or supporting EPT,135  other jurisdictions including New York,136
Wisconsin, 137 and Massachusetts 138 have recently introduced related bills. Additional
legislative activity may be stimulated by the production of model statutory language
supporting the practice of EPT. The Center and CDC are currently exploring a project
to develop model language that explains and authorizes the public health practice of
EPT and simultaneously attempts to resolve existing legal conflicts in those jurisdictions
whose legislatures or regulatory bodies may voluntarily choose to consider and enact the
model.
Adopt modem, updated national treatment guidelines. As noted, many
states incorporate by reference the treatment guidelines set forth by CDC and/or the
APHA. Advances in epidemiological science and public health practice, such as EPT,
are reflected in CDC's 2006 edition of its guidelines, but states' regulations may refer to
outdated editions of the guidelines and thus fail to incorporate the revisions in
subsequent versions. For example, the District of Columbia incorporates by reference
the Ninth edition of APHA's manual, published in 1960, and states that meeting its
requirements (which are now forty-seven years old) is prima facie evidence of good
medical or public health practice. 39 The 1960 version of the APHA manual could not
possibly include more modem public health interventions like EPT. By contrast,
Nevada incorporates the latest editions of APHA's manual and CDC's STD Treatment
Guidelines automatically, stating, "[A]ny revision to the above guidelines is effective 10
days after its revision unless the state health officer files an objection with the state
board of health." 140 As Nevada did, states should incorporate current versions of the
guidelines through automatic adoption to keep abreast of the latest developments in
public health, including the practice of EPT. Moreover, in states in which the public
health authority can designate the appropriate treatment guidelines for STDs in keeping
with recognized epidemiologic developments, the public health authority should
explicitly endorse EPT as an acceptable treatment practice for gonorrhea and chamydia.
Create exceptions to existing prescription requirements. As discussed in
Part III, prescription requirements can challenge the implementation of EPT by
requiring patient identifying information on prescription labels and prohibiting the
dispensation of drugs to individuals whom the physician has not examined. The laws of
135 See supra note 105.
136 Assemb. 8730, 2301h Legis. Sess. (N.Y. 2007).
137 Assemb. 318, 98t Legis. Sess. (Wis. 2007).
138 S 650, 183r Sess. (Ma. 2003).
139 D.C. MuN. REG. tit. 22 § 202.8 (2007).
140 NEV. ADMIN. CODE S 441A.200(1)(d), (f) (2007).
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thirty-eight jurisdictions require that prescription labels contain patient identifying
information (e.g., patient name and address). 141 These laws may require that the
medication's recipient or ultimate user-whether a patient or third party-be identified
on the label prior to dispensation. In the context of EPT, requiring this information
could undermine the recipient's anonymity and deter its practice. Regulatory exceptions
to prescription label requirements may facilitate EPT in practice by allowing clinicians to
provide "blank" prescriptions or an "extra dose" for the patient to deliver to the partner
for the treatment of STDs like chlamydia or gonorrhea.
Providing access to prescription medications for public health purposes to
persons whom a clinician has neither examined nor established a professional
relationship with may seem counterintuitive and inconsistent with sound medical
practice. A basic tenet of health care services in the United States is that clinicians
should not provide prescription medications to non-patients. There are, however,
exceptions to the basic rule. Physicians regularly give prescription medications to minor,
elderly, or mentally-disabled patients through parents, spouses, caregivers, or court-
appointed guardians. 142 Each year, public health practitioners provide flu vaccines
without significant clinical evaluation to individuals who request it. 143 After outbreaks
of meningococcal meningitis are detected in hospitals, hospital workers are given
antibiotics for them and their family members without advance clinical diagnosis.'"
Although these examples differ from EPT, they each are designed to ensure that safe,
effective medications are delivered to persons who need them, even without direct
medical evaluation of the recipients.
In addition to labeling requirements, thirteen jurisdictions statutorily prohibit
pharmacists from dispensing medications to individuals (1) who have not undergone a
physical examination, (2) who have failed to establish a physician-patient relationship, or
(3) who are not the ultimate user (i.e. a third-party is the ultimate user) pursuant to a
valid prescription. 145 Since a patient's sexual partner would invariably fall within one of
141 See Legal Status of Expedited Partner Therapy, supra note 1.
142 Peter S. Arno, et al., The Economic Value of Informal Caregvin HEALTH AFFAIRS March-Apr.
1999, at 182-88; Am. Med. Ass'n., Health Risks: Issues and Risks in Caregivin, available at
http://www.ama-assn.org/ama/pub/category/8802.html (last visited Apr. 1, 2008).
143 Tricia Bishop, Pupils to get Free Flumist: State Will Dispense 250,000 Doses of MedImmune Vacine.
BALTIMORE SUN, Sept. 14, 2006, at 1D.
144 Hodge et al., supra note 1.
145 Id.; see, e.g., ARK. CODE ANN. § 17-92-505 (2008); FLA. STAT. § 465.023 (2007); HAW. REV.
STAT. § 328-16(b)(3) (2007); KAN. STAT. ANN. § 65-1626(g) (2006); 247 MASS. CODE REGS. 2.00
(2008); MICH. COMP. LAWS ANN. § 333.17751 (2008); OHIO ADMIN. CODE 4729:5-30(A) (2007);
OKLA. ADMIN. CODE § 535:15-3-13(d) (2006); S.C. CODE ANN. § 40-43-86 (2006); TEx. Occ.
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these categories, pharmacists may be legally prohibited from dispensing medications to
patients if the pharmacists are aware that an intended dosage is for their patients' sexual
partners. While helping to protect the public from unscrupulous acts of various
individuals, these prescription requirements should be reconsidered and reformed to
allow EPT in consideration of the greater public health benefits that stem from EPT.
Seek endorsements from medical boards. Most jurisdictions' laws do not
specify whether issuing a prescription without prior medical evaluation or outside the
physician-patient relationship is a per se instance of physician misconduct. Whether
such practices are generally barred as unprofessional may be left to the discretion of
medical or pharmaceutical licensing authorities. The Centers findings suggested that
fewer than half (48%) of the fifty-two assessed jurisdictions featured any opinions
(including Attorney General opinions) on EPT or like practices. 4 6 Of the twenty-five
states in which boards issued opinions, sixteen (64%) prohibited EPT or like
practices. 47 Opinions in nine (36%) states were more supportive. 14 8 In August 2006,
for example, the New Mexico Medical Board voted to amend the state's Medical
Practice Act to support EPT. 149 On a national level, the American Medical Association
has directly endorsed the practice of EPT as applied to chlamydia and gonorrhea1 50
Additional medical and pharmaceutical board opinions consistent with this national
trend would help resolve legal uncertainties concerning its practice even in states that
seek statutory or regulatory amendments.
Support insurance reimbursements for STD treatments for patients and
partners. While legal issues are the focus of this article, economic factors also have the
potential to complicate the practice of EPT. Questions may arise, for example, as to
who should front the costs of an extra dose of antibiotics for the sexual partners of
patients seeking treatment for chlamydia or gonorrhea. Who should pay - the patient,
the partner, or perhaps public health authorities? When patients, partners, or public
health authorities do not pay out-of-pocket for the prescription medications, should the
CODE ANN. S 291.104 (2007); W. VA. CODE § 30-5-3 (2007).
146 See Legal Status of Expedited Partner Therapy, supra note 1.
147 Id.
148 Id.
149 N.M. Med. Soc'y., Resolution B-204, availabk at http://www.nmms.org/subpages/NMMS_
actionMeet.htm. (last visited Apr. 1, 2008).
150 Am. Med. Ass'n, Poli9 D-440.968, Expedited Partner Therapy (Partner-Devered Partner Therapy),
available at http://www.ama-assn.org/apps/pfnew/pf_online?f n=browse&doc=policyfiles/
DIR/D-440.968.HTM (last visited Apr. 1, 2008); Council on Science and Public Health, REPORT
7 (A-06), available at http://www.ama-assn.org/ama/pub/category/16410.html (last visited Apr.
1, 2008).
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patient's health insurer cover the cost of two doses, even though the partner (who may
or may not be insured by the same provider) is the recipient of the extra dose? How can
the partner's health insurance company be expected to pay when the partner may not
ever be formally diagnosed with an STD? Though costs for antibiotics to treat these
STDs are typically low (depending on the form of medication),15' the costs are
compounded within a health insurance company that may be insuring hundreds or even
thousands of patients involved in EPT. Health insurance providers may (1) seek to deny
payment to the patient for the partner's "half" purely on the basis of cost savings and (2)
allege that patients have engaged in insurance fraud by attempting to receive payments
for drugs for which they are not the ultimate user.
Denying payment for these medications actually runs counter to the medical
interests of the patient and partner for two primary reasons. First, the treatment of the
patient's partner with STDs is directly tied to improving the health of the patient (which
the provider is supposed to insure). Treating the partner may be the surest way to break
the cycle of STD transmission. Absent effective treatment for the patient and partner,
the patient likely will be infected again. Second, only through the preventive treatment
of STDs like chlamydia and gonorrhea may more significant medical complications,
addressed in Part II, be averted. just as with many public health preventive measures,
spending a small amount of money initially to prevent the spread of a disease or treat it
early ultimately saves significant health care resources. Health insurers seeking to save
dollars by denying payment for the extra dose of inexpensive antibiotics to partners may
increasingly face the much greater costs of treating the long-term morbidity of patients
with STDs. Accordingly, laws and policies should support a health insurance provider's
payment for the patient's minimal expenses in delivering medications to partners
through EPT. This recommendation would not, of course, obligate a patient's health
insurer to pay the costs of any additional treatment for the partner.
Conclusion
Increasing rates of STD infections like chlamydia and gonorrhea in the United
States, diminishing public health resources, and low efficacy of traditional partner
management practices present significant public health challenges. In the face of these
challenges, public health authorities have crafted new strategies to limit the spread of
STDs. By combining patient-based partner notification with medical treatment and
education for partners, EPT is a promising new approach for treating some STDs and
effectively breaking cycles of transmission among some patients. Given the paucity of
151 Hodge, et al., supra note 1.
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available public health resources nationally, EPT is both epidemiologically and
economically viable.
Yet the practice of EPT must confront barriers to succeed. Health care
practitioners, patients, and partners question the practice on the basis of perceived legal
impediments. Perceptions of illegality of EPT do not necessarily match reality. The
Center's and CDC's legal assessment suggests that laws in most jurisdictions either
expressly permit EPT or potentially allow it. Still, additional changes in law or its
interpretation may enhance the practice of EPT in many jurisdictions. Law- and policy-
makers should consider expressly adopting EPT via statutory or regulatory routes.
Pharmaceutical laws that may hinder EPT in practice should be reconsidered. Medical
and pharmaceutical boards should opine as to the legality or ethicality of EPT in their
jurisdictions. Insurance laws underlying the payment of patient claims should support
EPT. Together, these recommendations may help improve the legal environment for
the modern practice of EPT to the improvement of the public's health.
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